-+ 0.00%
-+ 0.00%
-+ 0.00%

Shanghai Pharmaceutical (601607.SH): Isoprenaline hydrochloride injection passed generic drug consistency evaluation

Zhitongcaijing·11/18/2026 08:41:13
Listen to the news

Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) issued an announcement. Recently, Shanghai Hefeng Pharmaceutical Co., Ltd. (“Shangyao Hefeng”), a subsidiary of the company, received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration for isopropyladrenaline hydrochloride injections. The drug passed the generic drug consistency evaluation.

According to reports, the indications for isoprenaline hydrochloride injection are: 1. Treatment of cardiogenic or infectious shock; 2. Treatment of complete atrioventricular block and cardiac arrest. In July 2025, Shanghai Hefeng submitted a supplementary application to the State Drug Administration for the consistent evaluation of the quality and efficacy of the generic drug and was accepted. As of the announcement date, the company has invested about 4.44 million yuan in research and development expenses for the drug's consistency evaluation.